ALPHAHELIX MOL.DIAGN. SK1 Total Assets
ALPHAHELIX MOL.DIAGN. SK1 total assets. Based on the latest financial reports, ALPHAHELIX MOL.DIAGN. SK1 (4MB) holds total assets worth €18.96 Million EUR (≈ $22.17 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 4MB company net worth for the company's overall valuation and market capitalisation.
Total Assets of ALPHAHELIX MOL.DIAGN. SK1 (2022–2025)
Total assets of ALPHAHELIX MOL.DIAGN. SK1 from 2022 to 2025. This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's total assets have evolved over time, based on quarterly financial data. See ALPHAHELIX MOL.DIAGN. SK1 stock price for real-time trading data and today's change.
ALPHAHELIX MOL.DIAGN. SK1 - Asset Composition Analysis
ALPHAHELIX MOL.DIAGN. SK1 Total Assets Breakdown (December 2025)
ALPHAHELIX MOL.DIAGN. SK1 total assets breakdown as of December 2025. ALPHAHELIX MOL.DIAGN. SK1's total assets of €18.96 Million consist of 90.9% current assets and 9.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.7% |
| Accounts Receivable | €5.53 Million | 39.4% |
| Inventory | €3.86 Million | 27.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €606.44K | 4.3% |
| Goodwill | €334.40K | 2.4% |
Asset Composition Trend (2022–2025)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of ALPHAHELIX MOL.DIAGN. SK1 to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALPHAHELIX MOL.DIAGN. SK1's current assets represent 90.9% of total assets in 2025, an increase from 69.7% in 2022.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, down from 27.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 25.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 39.4% of total assets.
ALPHAHELIX MOL.DIAGN. SK1 Competitors by Total Assets
Key competitors of ALPHAHELIX MOL.DIAGN. SK1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonza Group AG
SW:LONN
|
Switzerland | CHF18.26 Billion |
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.42 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
ALPHAHELIX MOL.DIAGN. SK1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 1.01 | 1.20 |
| Quick Ratio | 0.38 | 0.63 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.53 Million | €93.00K | €1.86 Million |
ALPHAHELIX MOL.DIAGN. SK1 - Advanced Valuation Insights
This section examines the relationship between ALPHAHELIX MOL.DIAGN. SK1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.43 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | €14.05 Million |
| Market Capitalization | $839.64K USD |
Valuation Analysis
Below Book Valuation: The market values ALPHAHELIX MOL.DIAGN. SK1's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ALPHAHELIX MOL.DIAGN. SK1's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ALPHAHELIX MOL.DIAGN. SK1 (2022–2025)
The table below shows the annual total assets of ALPHAHELIX MOL.DIAGN. SK1 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.05 Million ≈ $16.43 Million |
-8.60% |
| 2024-12-31 | €15.37 Million ≈ $17.97 Million |
-19.49% |
| 2023-12-31 | €19.09 Million ≈ $22.32 Million |
-33.71% |
| 2022-12-31 | €28.80 Million ≈ $33.67 Million |
-- |
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (p… Read more